Researchers identify new cancer cell death mechanism using eliglustat drug
Scientists found that inhibiting glucosylceramide synthase triggers cancer cell death independent of pro-death ceramide levels, using an existing therapy.
FTMQ Science, written by our newsroom0 views
Researchers at the VCU Massey Comprehensive Cancer Center have discovered that inhibiting the enzyme glucosylceramide synthase causes cell death in cancer cells through a previously unknown mechanism. EurekAlert! reported that this cell death occurs independently of changes in pro-death ceramide levels. The findings were published in the journal Cell Death Discovery. [1]
The research team used eliglustat, an animal and human drug approved by the Food and Drug Administration, to successfully induce cell death across several cancer cell lines. EurekAlert! reported that the study was led by Addi Can Senkal, interim director of the Lipidomics and Metabolomics Shared Resource at Massey, and Alexandra Straus, a post-doctoral fellow in the VCU Department of Cellular, Molecular and Genetic Medicine. [1]
The VCU Massey Comprehensive Cancer Center is a non-profit organization located in Richmond, Virginia. Founded in 1974, it operates as part of Virginia Commonwealth University. [2]
As FTMQ Science reported earlier, researchers in Virginia have also been exploring other targeted approaches to oncology, including ultrasound-guided genetic therapies for glioblastoma. The new findings from Massey highlight ongoing efforts to repurpose targeted chemical treatments to trigger alternative cell death pathways in malignant cells. [1][3]
In short
- Inhibiting glucosylceramide synthase induces cell death in cancer cell lines independently of pro-death ceramide levels.
- Researchers used the FDA-approved drug eliglustat to demonstrate the mechanism in multiple cancer cell lines.
- The findings were published in the scientific journal Cell Death Discovery.
- The study was conducted by researchers at the VCU Massey Comprehensive Cancer Center.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]VCU Massey Comprehensive Cancer Center researchers showcase new mechanism to target glucosylceramide synthase in cancer therapyEurekAlert!, 8d ago (the report this story comes from)
Background
- [2]VCU Massey Comprehensive Cancer Center on Wikipedia
- [3]Researchers combine focused ultrasound and microRNAs to combat glioblastoma FTMQ Science, 16d ago
- [4]Personalised mRNA melanoma vaccine expected to secure approval next year FTMQ Science, 25d ago
Our newsroom writes these reports with the help of software, from the 4 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from FTMQ Science
Earlier reports of ours on the same people and subjects.
- Personalised mRNA melanoma vaccine expected to secure approval next yearTop Stories, 25d ago
- Viscous fluid around brain tumors increases glioblastoma invasivenessBody & Mind, 24d ago
- Shanghai dismisses researchers following child gene editing trial deathNew Research, 3d ago
- Researchers propose a method to detect hypothetical mirror life using lightBiology, 24d ago
- Scientists identify heme in dinosaur fossil from BrazilTop Stories, 11d ago
More in Top Stories
- United States loses measles elimination status after year of continuous spread5h ago
- Physicists at CERN detect extremely rare particle interaction at zeptometer scale5h ago
- Researchers find evidence of massive ancient Baffin Bay ice shelf5h ago
- Excavations in southern Saudi Arabia reveal 125,000 year old prehistoric human site2d ago
- Ancient Danish skeleton shows individual dietary transition to farming2d ago
- Ancient Danish skeleton provides insights into shift to agriculture2d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.